Navigation Links
Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
Date:11/18/2009

NEWTOWN SQUARE, Pa., Nov. 18 /PRNewswire/ -- A panel of osteoarthritis (OA) key opinion leaders has developed a consensus of the optimal exogenous hyaluronic acid (HA) treatment. This consensus was achieved by utilizing what the experts referred to as BioRestorative(TM) Profiling. This profiling examines HAs on the basis of their mimicking the body's natural HA. "BioRestorative(TM)" describes the features of the ideal HA product, based on the treatment goals of symptom relief, improvement in function, and improved quality of life. In a comparison of available HA products, EUFLEXXA® (1% sodium hyaluronate) best matched the BioRestorative profile. Results of the panel's discussion were published in an independent educational publication authored by members of The Institute for Clinical Care, accessible at www.clincare.org. The report was sponsored by Ferring Pharmaceuticals Inc., the maker of EUFLEXXA®, and published by Dardine & Associates, LLC.

Features of the Ideal HA Product

The panel hypothesized that the exogenous HA product likely to yield the best results in OA treatment is one that most closely resembles endogenous human HA in all ways, including size, structure and molecular weight. The ideal HA would have high viscosity and high molecular weight. When injected, it would supplement the synovial fluid inside the knee and lubricate and protect the joint. The product would also be as pure as possible, containing no contaminants or animal proteins. A low protein concentration lowers the risk of inflammatory reactions and pseudosepsis.

"The term 'BioRestorative' suggests that an ideal HA has a restorative effect on naturally occurring synovial fluid in the joint," said panel leader Dr. Jeffrey E. Rosen, Chairman, Department of Orthopaedics and Physical Medicine & Rehabilitation at New York Hospital Queens. "Of the currently marketed HA products, non-avian EUFLEXXA® most closely fits the BioRestorative profile. It has ultra-high purity, high molecular weight, and minimal protein content."

About HA Treatment

In the joint, HA is essential to water balance, viscosity, lubrication and the structure of cartilage. It provides a cushion to protect the inside of the joint from mechanical damage and acts as a shock-absorbing fluid and regulator of water and metabolites. In synovial fluid, HA binds to other molecules, helping it withstand weight-bearing force and movement of the joint. Injections into the joint have been shown to provide long-term improvement of the quantitative and qualitative properties of endogenous HA, increasing joint lubrication and reducing pain.(1) Most current products are avian-derived, and two are bioengineered via fermentation of bacteria.

About The Institute for Clinical Care

The Institute for Clinical Care was established in 2005 to facilitate the development and dissemination of timely and clinically relevant educational programming sponsored by respected institutional and nonprofit providers of continuing education for healthcare providers. The clinical authorities with whom the Institute works are recognized leaders in their field. It is under their direction and with their contribution and approval that the content for the Institute's educational offerings are developed.

(1) Hempfling H. Intra-articular hyaluronic acid after knee arthroscopy: a two-year study. Knee Surg Sports Traumatol Arthrosc. 2007;14(3):537-546.

SOURCE The Institute for Clinical Care


'/>"/>
SOURCE The Institute for Clinical Care
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
2. Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair(R) System for Severe Asthma
3. Varian Medical Systems to Exhibit a Wide Selection of Flat Panel X-Ray Image Detectors and X-Ray Tubes at the CMEF Show in Chengdu, China
4. Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development
5. GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
6. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
7. FDA Advisory Panel Recommends Approval of the SEDASYS(R) System
8. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
9. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
10. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
11. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):